Marcella Fassò

4.1k total citations · 2 hit papers
42 papers, 2.9k citations indexed

About

Marcella Fassò is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marcella Fassò has authored 42 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 17 papers in Immunology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marcella Fassò's work include Cancer Immunotherapy and Biomarkers (30 papers), Immunotherapy and Immune Responses (13 papers) and CAR-T cell therapy research (12 papers). Marcella Fassò is often cited by papers focused on Cancer Immunotherapy and Biomarkers (30 papers), Immunotherapy and Immune Responses (13 papers) and CAR-T cell therapy research (12 papers). Marcella Fassò collaborates with scholars based in United States, France and Spain. Marcella Fassò's co-authors include Carol O’Hear, Luciana Molinero, William M. Ridgway, Michael S. Gordon, Leisha A. Emens, Joseph P. Eder, Rebecca Waitz, James P. Allison, Fadi Braiteh and C. Garrison Fathman and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Marcella Fassò

41 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

2018 567 citations Leisha A. Emens, Cristina Cruz et al. profile →
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

2016 409 citations David F. McDermott, Jeffrey A. Sosman et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Marcella Fassò

Since Specialization

Citations

This map shows the geographic impact of Marcella Fassò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcella Fassò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcella Fassò more than expected).

Fields of papers citing papers by Marcella Fassò

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcella Fassò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcella Fassò. The network helps show where Marcella Fassò may publish in the future.

Co-authorship network of co-authors of Marcella Fassò

This figure shows the co-authorship network connecting the top 25 collaborators of Marcella Fassò. A scholar is included among the top collaborators of Marcella Fassò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcella Fassò. Marcella Fassò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment 2023 ·JNCI Journal of the National Cancer Institute ·Shilpa Gupta, Alexander Andreev-Drakhlin, Otto Fajardo, Marcella Fassò, Jorge A. García, Christopher Eing Wee, Carsten Schröder	1
2	2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo) 2023 ·Annals of Oncology ·Shilpa Gupta, Omar Alhalabi, Aristotelis Bamias, Joaquim Bellmunt, (unknown), Jens Bedke, Terence W. Friedlander, Benjamin Garmezy, Petros Grivas, Robert Huddart, Andrea Necchi, Thomas Powles, Javier Puente, (unknown), (unknown), Chiara Lambertini, Alexander Andreev-Drakhlin, Marcella Fassò, Yohann Loriot	0
3	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study 2021 ·Clinical Cancer Research ·Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles	54
4	Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer 2020 ·Clinical Lung Cancer ·Anne C. Chiang, Lecia V. Sequist, Jill Gilbert, Paul Conkling, (unknown), Judith Marcoux, Scott Gettinger, Marcin Kowanetz, Luciana Molinero, Carol O’Hear, Marcella Fassò, Sivuonthanh Lam, Michael S. Gordon	17
5	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab 2019 ·Clinical Cancer Research ·Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi	58
6	Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers 2019 ·Gynecologic Oncology ·Joyce F. Liu, Michael S. Gordon, Jennifer Veneris, Fadi Braiteh, Ani Sarkis Balmanoukian, Joseph P. Eder, Ana Oaknin, Erika Hamilton, Yulei Wang, Indrani Sarkar, Luciana Molinero, Marcella Fassò, Carol O’Hear, Yvonne G. Lin, Leisha A. Emens	101
7	Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab 2019 ·Journal for ImmunoTherapy of Cancer ·Luciana Molinero, Yijin Li, Ching‐Wei Chang, Sophia L. Maund, (unknown), (unknown), Marcella Fassò, Carol O’Hear, Priti S. Hegde, Leisha A. Emens	25
8	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial 2018 ·Annals of Oncology ·A. Dimitrios Colevas, Rastislav Bahleda, Fadi Braiteh, Ani Sarkis Balmanoukian, Irene Braña, Nicole G. Chau, Indrani Sarkar, Luciana Molinero, William Grossman, Fairooz F. Kabbinavar, Marcella Fassò, Carol O’Hear, John D. Powderly	107
9	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma 2018 ·Journal of Neuro-Oncology ·Rimas V. Lukas, Jordi Rodón, Kevin Becker, Eric T. Wong, Kent C. Shih, Mehdi Touat, Marcella Fassò, Stuart Osborne, Luciana Molinero, Carol O’Hear, William Grossman, Joachim M. Baehring	112
10	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study 2018 ·European Journal of Cancer ·Leora Horn, Scott Gettinger, Michael S. Gordon, Roy S. Herbst, Leena Gandhi, Enriqueta Felip, Lecia V. Sequist, David R. Spigel, Scott Antonia, Ani Sarkis Balmanoukian, Philippe A. Cassier, Bo Liu, Marcin Kowanetz, Carol O’Hear, Marcella Fassò, William Grossman, Alan Sandler, Jean‐Charles Soria	46
11	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses 2017 ·Cancer Research ·Peter Schmid, Cristina Cruz, Fadi S. Braiteh, Joseph P. Eder, Sara M. Tolaney, Irene Kuter, Rita Nanda, Cathie T. Chung, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Yijin Li, Bo Liu, Carol O’Hear, Marcella Fassò, Luciana Molinero, Leisha A. Emens	92
12	Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC) 2016 ·Annals of Oncology ·J. R. Infante, Fadi Braiteh, Leisha A. Emens, Ani Sarkis Balmanoukian, Ana Oaknin, (unknown), (unknown), Luciana Molinero, Marcella Fassò, Carol O’Hear, Michael S. Gordon	36
13	PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study 2016 ·Journal of Thoracic Oncology ·Michael S. Gordon, Roy S. Herbst, Leora Horn, Jean‐Charles Soria, Leena Gandhi, Enriqueta Felip, Lecia V. Sequist, David R. Spigel, Scott Antonia, Ani Sarkis Balmanoukian, Philippe A. Cassier, Bo Liu, Marcin Kowanetz, Carol O’Hear, Marcella Fassò, Alan Sandler, Scott Gettinger	2
14	Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study breakdown → 2016 ·Journal of Clinical Oncology ·David F. McDermott, Jeffrey A. Sosman, Mario Sznol, Christophe Massard, Michael S. Gordon, Omid Hamid, John D. Powderly, Jeffrey R. Infante, Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hegde, Gregg Fine, Thomas Powles	409
15	Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC) 2016 ·Annals of Oncology ·Lecia V. Sequist, (unknown), Jennifer L. Gilbert, (unknown), Paul Conkling, (unknown), Judith Marcoux, S. Antonia, (unknown), David S. Shames, Ariel López-Chávez, Carol O’Hear, Marcella Fassò, Scott Gettinger	30
16	Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) 2015 ·Journal for ImmunoTherapy of Cancer ·Thomas Powles, Dorothee Nickles, Eliezer M. Van Allen, Colombe Chappey, Wei Zou, Marcin Kowanetz, Edward E. Kadel, Mitchell Denker, Zachary Boyd, Nicholas J. Vogelzang, Joseph Kim, Joaquim Bellmunt, Yohann Loriot, Charles G. Drake, Carol O’Hear, Marcella Fassò, Priti S. Hegde, Sanjeev Mariathasan	11
17	CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection 2012 ·OncoImmunology ·Rebecca Waitz, Marcella Fassò, James P. Allison	27
18	Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy 2011 ·Cancer Research ·Rebecca Waitz, Stephen B. Solomon, Elena N. Petre, Anne E. Trumble, Marcella Fassò, Larry Norton, James P. Allison	210
19	Following Antigen Challenge, T Cells Up-Regulate Cell Surface Expression of CD4 In Vitro and In Vivo 1998 ·The Journal of Immunology ·William M. Ridgway, Marcella Fassò, C. Garrison Fathman	54
20	Breaking self-tolerance in nonobese diabetic mice. 1996 ·The Journal of Experimental Medicine ·William M. Ridgway, Marcella Fassò, Amy Lanctot, Colin Garvey, C. Garrison Fathman	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact